Invitae, a leading medical genetics company, recently announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He will develop and implement Invitae’s commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of clients and patients.
The CEO on the new appointee
“I’m excited to welcome Rob to the leadership team as we sharpen our focus on expanding the size and number of pathways for profitable growth,” said Ken Knight, president and chief executive officer of Invitae. “Rob is a talented and innovative leader who has provided vision and led impactful change throughout his career. His deep understanding of the long-term prospects of genetic information, along with his extensive experience working with payers, make him the perfect choice to help guide the next phases of our journey.”
Mr. Guigley has led direct sales and marketing campaigns in a variety of roles. Most recently, he served as chief commercial officer at Ambry Genetics, responsible for executing their commercial strategy and overseeing commercial sales, business development, client services, managing genetic specialists and expanding market access.
Mr. Guigley began his career in pharmaceutical sales at AstraZeneca, giving him a strong foundation in selling to physicians. He then migrated into diagnostics, leading sales and market access at Quest Diagnostics and Counsyl. Mr. Guigley earned his MBA at Boston University Questrom School of Business and his BS at the University of Pittsburgh, where he focused on economics, math and philosophy.
The CCO on his appointment
“I’m excited to be joining Invitae and for the opportunity to support its mission to bring comprehensive genetic information into mainstream medicine,” said Rob Guigley, incoming chief commercial officer for Invitae. I’m looking forward to using my passion for patients and broad experience to develop an innovative commercial strategy for Invitae.”
For more appointment related news in the pharmaceutical industry:
CellPly welcomes Emiliano Spagnolo as the new CEO
Ligandal Inc. welcomes Tushar Nuwal as COO and CBO
Dr. Liu Jian joins Medicilon as President of Drug Discovery Division
